《公司業績》復宏漢霖-B(02696.HK)全年虧損擴大至9.94億元人民幣
復宏漢霖-B(02696.HK)公布截至去年12月底止全年業績,營業額5.88億元人民幣(下同),按年升546.2%。虧損擴大至9.94億元,上年同期蝕8.75億元;每股虧損1.88元。不派息。
去年研發臨床開支約17.11億元,按年增加21.6%。
公司指,今年將持續拓展覆蓋腫瘤、自身免疫性疾病及更多領域的生物藥產品管線,把握已取得的先發優勢,進一步推進集團創新型轉型以及國際化戰略的落地,完善生產基地建設、擴大生產能力,加速推動更多優質生物產品的商業化。
另外,公司目前未動用上市所得款項為7.17億元,審議了HLX10和腫瘤免疫療法的研發進度,並認為HLX10和腫瘤免疫療法的臨床試驗、監管備案及註冊需要額外投資,故將分配不同項目的資金作重新分配。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.